- Trials with a EudraCT protocol (5,931)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5,931 result(s) found for: Progression Free Survival.
Displaying page 1 of 297.
EudraCT Number: 2005-003327-39 | Sponsor Protocol Number: KKSH-14 | Start Date*: 2006-04-21 |
Sponsor Name:Martin-Luther-University | ||
Full Title: Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II... | ||
Medical condition: oligometastatic breast cancer | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003189-29 | Sponsor Protocol Number: ONCO-01-2017 | Start Date*: 2018-02-09 | |||||||||||
Sponsor Name:L'Institut Mutualiste Montsouris | |||||||||||||
Full Title: A phase II/III multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer | |||||||||||||
Medical condition: Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression on the PSAWG3 criteria) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003031-38 | Sponsor Protocol Number: GOIRC-05-2016 | Start Date*: 2017-04-04 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
Full Title: Phase II randomized study of maintenance Regorafenib vs Placebo in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metas... | |||||||||||||
Medical condition: No progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metastatic gastric or gastroesophagel junction cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002295-41 | Sponsor Protocol Number: PR2100 | Start Date*: 2009-01-29 |
Sponsor Name:The University of Birmingham | ||
Full Title: A randomised phase II/III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolo... | ||
Medical condition: Hormone refractory Prostate Cancer (HRPC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021863-34 | Sponsor Protocol Number: RHMCAN0739 | Start Date*: 2011-02-10 |
Sponsor Name:University Hospital Southampton NHS Foundation Trust | ||
Full Title: A phase II trial of the addition of ipilumimab to carboplatin and etoposide chemotherapy for the first line treatment of extensive small cell lung cancer | ||
Medical condition: Extensive stage small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002991-15 | Sponsor Protocol Number: SOLTI-1804 | Start Date*: 2019-11-04 |
Sponsor Name:SOLTI | ||
Full Title: HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302 | ||
Medical condition: Her2‑positive, unresectable and/or metastatic breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001939-38 | Sponsor Protocol Number: NIVINIHO | Start Date*: 2018-04-18 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions | |||||||||||||
Medical condition: patients aged 61 years and older, with classical Hodgkin lymphoma and coexisting medical conditions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002400-40 | Sponsor Protocol Number: FFCD1709 | Start Date*: 2020-07-27 |
Sponsor Name:Fédération Francophone de Cancérologie Digestive | ||
Full Title: A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB (IMMUNE CHEKPOINT INHIBITOR) ... | ||
Medical condition: MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001938-42 | Sponsor Protocol Number: UCL-ONCO2011-01 | Start Date*: 2012-01-24 |
Sponsor Name:Cliniques universitaires Saint-Luc | ||
Full Title: Randomized Phase II Study of CABAZITAXEL versus METHOTREXATE in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy | ||
Medical condition: To evaluate the efficacy of cabazitaxel in patients with palliative head and neck previously treated with platinum-based therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000082-41 | Sponsor Protocol Number: 2021-0486 | Start Date*: 2022-03-31 |
Sponsor Name:Fundación para la Investigación en Urología | ||
Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial | ||
Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004438-24 | Sponsor Protocol Number: M14-483 | Start Date*: 2015-06-23 | ||||||||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||||||||||||||||||
Full Title: INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group. | ||||||||||||||||||
Medical condition: Glioblastoma Multiforme For Pediatric - High Grade Glioma and DIPG | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) DE (Completed) HU (Completed) AT (Completed) FI (Completed) GB (Completed) IE (Completed) ES (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004388-37 | Sponsor Protocol Number: 69HCL19_0457 | Start Date*: 2020-03-03 | ||||||||||||||||
Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
Full Title: A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural and Malignant Peritoneal MESOthelioma Pa... | ||||||||||||||||||
Medical condition: This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma. The cohorts B1 will be patient populations with non-resected or incomp... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002767-26 | Sponsor Protocol Number: LyRICX | Start Date*: 2019-06-25 |
Sponsor Name:Academic Medical Center | ||
Full Title: Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) | ||
Medical condition: gastroesophageal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005141-16 | Sponsor Protocol Number: NL75539.078.20 | Start Date*: 2021-06-23 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study. | |||||||||||||
Medical condition: non-metastatic resectable pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000345-70 | Sponsor Protocol Number: M12-914 | Start Date*: 2014-07-01 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Veliparib (ABT-888) in Her-2 Negative Metastatic or Locally Advanced Unresectable B... | |||||||||||||
Medical condition: HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated mutation (BRCA1 and BRCA2) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) AT (Prematurely Ended) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) PT (Completed) DE (Prematurely Ended) BE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) IT (Prematurely Ended) NL (Completed) LV (Completed) ES (Prematurely Ended) FR (Prematurely Ended) LT (Completed) EE (Ongoing) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000547-14 | Sponsor Protocol Number: BGOG-cx3 | Start Date*: 2017-08-30 | |||||||||||
Sponsor Name:BGOG-UZLeuven | |||||||||||||
Full Title: BGOG-cx3: Prospective randomized Phase II trial comparing doxorubicin alone versus doxorubicin and atezolizumab in recurrent cervical cancer | |||||||||||||
Medical condition: recurrent cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003996-23 | Sponsor Protocol Number: SAKK08/16 | Start Date*: 2017-08-29 | |||||||||||
Sponsor Name:SAKK | |||||||||||||
Full Title: ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and nonprogressive disease after sec... | |||||||||||||
Medical condition: Metastatic castration resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002973-23 | Sponsor Protocol Number: GAP | Start Date*: 2013-11-07 |
Sponsor Name:Fondazione GISCAD | ||
Full Title: A Phase II randomized trial comparing a combination of Abraxane and Gemcitabine versus Gemcitabine alone as first line treatment in locally advanced unresectable pancreatic cancer. | ||
Medical condition: 124 locally advanced unresectable pancreatic cancer patients will be randomized in a 1:1 ratio to receive abraxane/gemcitabine (arm A) or gemcitabine alone (arm B), as first-line chemotherapy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003021-19 | Sponsor Protocol Number: BCPP2005-01 | Start Date*: 2006-08-22 |
Sponsor Name:University Of Birmingham | ||
Full Title: The use of selenium and vitamin E supplementation to prevent recurrence and progression of non-muscle-invasive bladder cancer | ||
Medical condition: Non-muscle-invasive transitional cell carcinoma of the bladder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018661-35 | Sponsor Protocol Number: C21004 | Start Date*: 2010-10-14 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant... | |||||||||||||
Medical condition: Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) HU (Completed) EE (Completed) BE (Completed) SK (Completed) LV (Completed) FI (Completed) NL (Completed) ES (Completed) LT (Completed) CZ (Completed) AT (Completed) GB (Completed) PT (Completed) SE (Completed) IE (Completed) DE (Completed) PL (Completed) IT (Completed) BG (Completed) GR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.